Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases

Mohamed, Nura A.; Marei, Isra; Crovella, Sérgio; Abou-Saleh, Haissam

doi:10.3390/ijms23031404

Cited by 35 publications

(18 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Over recent decades, nanotechnology has arrived in many fields and actuated the whole world to phenomenal developments. Meanwhile, the pharmaceutical industry has not been an exception, and new nanopharmaceutical products have entered different markets ( Wang et al., 2021 ; Mohamed et al., 2022 ). In the past two decades, the pattern of using nanocarriers in the human body to enhance the efficacy and effectiveness of many drugs, especially anticancer drugs, has been well confirmed in both pharmaceutical and clinical experiments.…”

Section: Plgamentioning

confidence: 99%

PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm

Shariati

Chegini

Ghaznavi‐Rad

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

The biofilm community of microorganisms has been identified as the dominant mode of microbial growth in nature and a common characteristic of different microorganisms such as Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis. The biofilm structure helps in the protection from environmental threats including host immune system and antimicrobial agents. Thus, the biofilm community has led to a higher prevalence of multidrug-resistant (MDR) strains in recent years. In this regard, the use of a new class of antibiotics, natural compounds, and anti-biofilm enzymes has been considered for the destruction of the microbial biofilm. However, different drawbacks such as low penetration, high susceptibility to degradation, instability, and poor solubility in aqueous solutions limit the use of anti-biofilm agents (ABAs) in a clinical setting. As such, recent studies have been using poly lactic-co-glycolic acid (PLGA)-based nanoplatforms (PLGA NPFs) for delivery of ABAs that have reported promising results. These particles, due to proper drug loading and release kinetics, could suppress microbial attachment, colonization, and biofilm formation for a long time. Additionally, PLGA NPFs, because of the high drug-loading efficiencies, hydrophilic surface, negative charge, and electrostatic interaction, lead to effective penetration of antibiotics to the deeper layer of the biofilm, thereby eliminating the microbial biofilm. Thus, PLGA NPFs could be considered as a potential candidate for coating catheters and other medical material surfaces for inhibition and destruction of the microbial biofilm. However, the exact interaction of PLGA NPFs and the microbial biofilm should be evaluated in animal studies. Additionally, a future goal will be to develop PLGA formulations as systems that can be used for the treatment of the MDR microbial biofilm, since the exact interactions of PLGA NPFs and these biofilm structures are not elucidated. In the present review article, we have discussed various aspects of PLGA usage for inhibition and destruction of the microbial biofilm along with different methods and procedures that have been used for improving PLGA NPF efficacy against the microbial biofilm.

show abstract

Section: Plgamentioning

confidence: 99%

PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm

Shariati

Chegini

Ghaznavi‐Rad

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

show abstract

“…The physicochemical properties of NPs, for example, molecular weight of cargos, NPs size, shape, and surface charge, and even chirality, affect its biodistribution in the body, drug-carrying capacity, residence time in the joint cavity, and in vivo pharmacokinetics. [198][199][200] However, both macromolecules (usually >10 kDa) and small molecules (<10 kDa) tend to leave the synovial fluid through the lymphatic system and capillary network due to the constant exchange of synovial fluid with the surrounding lymphatic fluid and blood, resulting in ineffective treatment. [35,201] The current molecular mass and hydrodynamic radius of conventional drugs for treating OA are NSAID (0.35 nm, 0.2 KDa), glucocorticoids (0.35 nm, 0.4 KDa), growth factors (2 nm, 0.4 KDa), and antibodies (5 nm, 150 KDa).…”

Section: Influence Of Physicochemical Properties Of Nps On Drug Deliv...mentioning

confidence: 99%

Analysis of Nanomedicine Efficacy for Osteoarthritis

Wang

Liu

et al. 2022

Advanced NanoBiomed Research

View full text Add to dashboard Cite

Osteoarthritis (OA) is a chronic disease and it causes considerable medical and socioeconomic burden. Currently, OA can be classified into different stages depending on its severity, from mild to severe, but there is no treatment focusing on a particular stage. In addition, conventional treatments suffer from drawbacks such as the poor effectiveness of physiotherapy, short‐term efficacy of medication, and invasiveness of surgery. Nanomedicine is a promising approach to improve OA treatments such as by prolonging the residence time of drugs in the joint and on‐demand drug release. Herein, the pathological development of OA and the cellular involvement in this process is reviewed and classified into three stages: early, intermediate, and advanced, according to its pathology and severity. Subsequently, nanomaterials that have been used to deliver drug cargo relevant to different stages of OA are reviewed. The impact of nanomaterial physicochemical properties, on therapeutic efficacy, is discussed. This is concluded by discussing the significance of minimum information reporting to standardize the use of nanomedicine for OA treatment and the potential of emerging methods including microneedles and DNA barcoding technology to improve the understanding of OA biology and improve clinical translation.

show abstract

“…The application of nanoparticles (NPs) to diagnose, treat and control various diseases represents a tremendous advancement in nanotechnology and nanomedicine ( Mohamed et al, 2022 ). Notably, a nanoparticle drug delivery system (NDDS) is a remarkable advancement in nanomedicine that employs nano-size particles to diagnose and control the delivery of various curative agents to the target cell/tissue ( Patra et al, 2018 ).…”

Section: Recent Advances and Prospectsmentioning

confidence: 99%

“…The nanoparticle delivery system ensures targeted and sustained delivery, enhanced drug bioavailability, and improved drug pharmaco-efficiency, as illustrated in Figure 5 . Thus, its road application in delivering immunotherapeutic, chemotherapeutic, and biological agents in managing diseases ( Ventola, 2017 ; Patra et al, 2018 ; Naidu et al, 2021 ; Mohamed et al, 2022 ).…”

Section: Recent Advances and Prospectsmentioning

confidence: 99%

Nanodelivery of antiretroviral drugs to nervous tissues

et al. 2022

View full text Add to dashboard Cite

Despite the development of effective combined antiretroviral therapy (cART), the neurocognitive impairments associated with human immunodeficiency virus (HIV) remain challenging. The presence of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCFB) impedes the adequate penetration of certain antiretroviral drugs into the brain. In addition, reports have shown that some antiretroviral drugs cause neurotoxicity resulting from their interaction with nervous tissues due to long-term systemic exposure. Therefore, the research into the effective therapeutic modality that would cater for the HIV-associated neurocognitive disorders (HAND) and ART toxicity is now receiving broad research attention. Thus, this review explores the latest information in managing HAND using a nanoparticle drug delivery system (NDDS). We discussed the neurotoxicity profile of various approved ART. Also, we explained the applications of silver nanoparticles (AgNPs) in medicine, their different synthesis methods and their interaction with nervous tissues. Lastly, while proposing AgNPs as useful nanoparticles in properly delivering ART to enhance effectiveness and minimize neurocognitive disorders, we hypothesize that the perceived toxicity of AgNPs could be minimized by taking appropriate precautions. One such precaution is using appropriate reducing and stabilizing agents such as trisodium citrate to reduce silver ion Ag + to ground state Ag0 during the synthesis. Also, the usage of medium-sized, spherical-shaped AgNPs is encouraged in AgNPs-based drug delivery to the brain due to their ability to deliver therapeutic agents across BBB. In addition, characterization and functionalization of the synthesized AgNPs are required during the drug delivery approach. Putting all these factors in place would minimize toxicity and enhance the usage of AgNPs in delivering therapeutic agents across the BBB to the targeted brain tissue and could cater for the HIV-associated neurocognitive disorders and neurotoxic effects of antiretroviral drugs (ARDs).

show abstract

Recent Developments in Nanomaterials-Based Drug Delivery and Upgrading Treatment of Cardiovascular Diseases

Cited by 35 publications

References 126 publications

PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm

PLGA-Based Nanoplatforms in Drug Delivery for Inhibition and Destruction of Microbial Biofilm

Analysis of Nanomedicine Efficacy for Osteoarthritis

Nanodelivery of antiretroviral drugs to nervous tissues

Contact Info

Product

Resources

About